Platinum-Resistant Lung Small Cell Carcinoma Recruiting Phase 1 Trials for Topotecan (DB01030)

IndicationStatusPhase
DBCOND0118884 (Platinum-Resistant Lung Small Cell Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05353439Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerTreatment